Amneal Pharmaceuticals (AMRX) Accumulated Depreciation & Amortization: 2017-2024
Historic Accumulated Depreciation & Amortization for Amneal Pharmaceuticals (AMRX) over the last 1 years, with Dec 2024 value amounting to $563.5 million.
- Amneal Pharmaceuticals' Accumulated Depreciation & Amortization rose 10.92% to $563.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.9 billion, marking a year-over-year increase of 13.77%. This contributed to the annual value of $563.5 million for FY2024, which is 10.92% up from last year.
- Latest data reveals that Amneal Pharmaceuticals reported Accumulated Depreciation & Amortization of $563.5 million as of Q4 2024, which was up 10.92% from $508.0 million recorded in Q4 2023.
- Amneal Pharmaceuticals' Accumulated Depreciation & Amortization's 5-year high stood at $563.5 million during Q4 2024, with a 5-year trough of $332.1 million in Q4 2020.
- Moreover, its 3-year median value for Accumulated Depreciation & Amortization was $508.0 million (2023), whereas its average is $505.8 million.
- Data for Amneal Pharmaceuticals' Accumulated Depreciation & Amortization shows a peak YoY rose of 20.32% (in 2020) over the last 5 years.
- Amneal Pharmaceuticals' Accumulated Depreciation & Amortization (Quarterly) stood at $332.1 million in 2020, then rose by 18.79% to $394.6 million in 2021, then climbed by 13.03% to $446.0 million in 2022, then climbed by 13.91% to $508.0 million in 2023, then increased by 10.92% to $563.5 million in 2024.
- Its Accumulated Depreciation & Amortization stands at $563.5 million for Q4 2024, versus $508.0 million for Q4 2023 and $446.0 million for Q4 2022.